Pivotal Phase III BouNDless Trial for Parkinson’s Disease Patients with Motor Fluctuations
Dr. Ryan Case, PhD, Head of Clinical Medical Affairs at Neuroderm, a Mitsubishi Tanabe Pharma Corporation (MTPC), discusses the highly positive results from the pivotal Phase III BouNDless trial evaluating ND0612 in Parkinson’s disease patients with motor fluctuations. ND0612 is a drug-device combination therapy – a 24 hours/day, continuous subcutaneous infusion of liquid levodopa/carbidopa (LD/CD) for people with Parkinson’s disease experiencing motor fluctuations.
Frequently Asked Questions
What is the main topic discussed in this episode of Health Professional Radio?
This episode covers important developments in healthcare, including updates on Therapy. Health Professional Radio brings you expert insights and analysis on the latest medical news affecting healthcare professionals and patients alike.
How can healthcare professionals benefit from this information?
Healthcare professionals can stay informed about the latest developments in Therapy and related fields, enabling them to provide better patient care. Staying current with medical news helps clinicians make evidence-based decisions in their practice.
Where can I find more information about Therapy?
For more detailed information, listen to the full episode on Health Professional Radio and visit hpr.fm for additional resources. You can also subscribe to our podcast for regular updates on healthcare news and expert interviews.
Ryan Case, PhD, has over 15 years of diverse experience developing innovative medical therapies for patients in need. While he’s worked in several therapeutics areas, he’s spent the last decade primarily focused on neuroscience and has a love for the field of Parkinson’s disease. He joined NeuroDerm, a wholly owned subsidiary of Mitsubishi Tanabe Pharma Corporation, in 2017 and leads medical affairs activities for the company. With the recent positive results from the BouNDless trial, he’s excited to continue supporting the exploration of ND0612’s potential to be an effective, well-tolerated treatment option to better control motor fluctuations in patients with Parkinson’s disease.
Medical Disclaimer
The information provided on this website is for general informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional for medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
